Current polygenic risk scores have limited performance predicting cardiometabolic and cardiovascular disease risk in diverse breast cancer survivors, necessitating new PGS development.
Do polygenic risk scores (PGS) accurately predict the risk for cardiometabolic and cardiovascular disease events in a multiethnic cohort of breast cancer survivors?
Current polygenic risk scores have limited performance in predicting cardiometabolic and cardiovascular events in breast cancer survivors, highlighting the need for de novo, ancestrally diverse PGS development.
Absolute Event Rate: 0% vs 0%
Although there may be potential value of PGS in predicting the risk for CMD and CVD events in women with histories of breast cancer, current PGS performance is limited. This work highlights the need to develop de novo PGS in breast cancer patients and to include ancestrally diverse patient populations.
Fiorica et al. (Sun,) reported a other. Current polygenic risk scores have limited performance predicting cardiometabolic and cardiovascular disease risk in diverse breast cancer survivors, necessitating new PGS development.